Tenor Capital Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.47K Hold
250,000
﹤0.01% 467
2025
Q4
$10K Hold
250,000
﹤0.01% 391
2025
Q3
$19.9K Hold
250,000
﹤0.01% 337
2025
Q2
$31.2K Hold
250,000
﹤0.01% 288
2025
Q1
$35.8K Hold
250,000
﹤0.01% 213
2024
Q4
$52.4K Hold
250,000
﹤0.01% 186
2024
Q3
$50K Hold
250,000
﹤0.01% 167
2024
Q2
$50K Hold
250,000
﹤0.01% 173
2024
Q1
$45.5K Hold
250,000
﹤0.01% 202
2023
Q4
$20K Hold
250,000
﹤0.01% 211
2023
Q3
$12.5K Hold
250,000
﹤0.01% 249
2023
Q2
$35K Hold
250,000
﹤0.01% 224
2023
Q1
$50K Hold
250,000
﹤0.01% 260
2022
Q4
$7.5K Hold
250,000
﹤0.01% 447
2022
Q3
$15K Hold
250,000
﹤0.01% 543
2022
Q2
$23K Hold
250,000
﹤0.01% 573
2022
Q1
$65K Hold
250,000
﹤0.01% 563
2021
Q4
$368K Hold
250,000
0.01% 481
2021
Q3
$370K Hold
250,000
0.01% 424
2021
Q2
$288K Hold
250,000
0.01% 466
2021
Q1
$205K Hold
250,000
0.01% 480
2020
Q4
$363K Hold
250,000
0.01% 270
2020
Q3
$295K Hold
250,000
0.01% 222
2020
Q2
$250K Hold
250,000
0.01% 157
2020
Q1
$163K Buy
+250,000
New +$196K 0.01% 152

Other funds holding JSPRW

Tenor Capital Management's JSPRW Position: Q1 2026 in Review

Tenor Capital Management held its Japer Therapeutics Warrants (JSPRW) position steady in Q1 2026 at 250,000 shares worth $5.47K. The position accounts for ﹤0.01% of the portfolio, ranked #467.

Tenor Capital Management first reported a position in JSPRW in Q1 2020 and has held it in 25 quarters since. The position peaked at $370K in Q3 2021. 7 funds tracked by Wall St. Rank hold JSPRW as of Q1 2026.

  • Tenor Capital Management held 250,000 shares of Japer Therapeutics Warrants worth $5.47K as of Q1 2026.
  • Tenor Capital Management left its Japer Therapeutics Warrants share count unchanged in Q1 2026.
  • Japer Therapeutics Warrants made up ﹤0.01% of Tenor Capital Management's portfolio in Q1 2026, its #467 holding.
  • Tenor Capital Management first reported a position in Japer Therapeutics Warrants in Q1 2020 and has held it in 25 quarters since.
  • Tenor Capital Management's Japer Therapeutics Warrants position peaked at $370K in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q1 2026.

Based on Tenor Capital Management's 13F filing for Q1 2026, filed 15 May 2026.